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Abstract: An anti-fibrotic compound produced by Streptomyces xiamenensis, found in 
mangrove sediments, was investigated for possible therapeutic effects against fibrosis.  
The compound, N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-methyl-3′S-pentenyl)-2H-
1-benzopyran-6-yl]carbonyl]-threonine (1), was isolated from crude extracts and its 
structure, including the absolute configuration was determined by extensive spectroscopic 
data analyses, Mosher’s method, Marfey’s reagent and quantum mechanical calculations. 
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In terms of biological effects, this compound inhibits the proliferation of human lung 
fibroblasts (WI26), blocks adhesion of human acute monocytic leukemia cells (THP-1) to a 
monolayer of WI26 cells, and reduces the contractile capacity of WI26 cells in   
three-dimensional free-floating collagen gels. Altogether, these data indicate that we have 
identified a bioactive alkaloid (1) with multiple inhibitory biological effects on lung 
excessive fibrotic characteristics, that are likely involved in fibrosis, suggesting that this 
molecule might indeed have therapeutic potential against fibrosis. 
Keywords:  Streptomyces xiamenensis; mangrove; benzopyran; fibroblast; anti-fibrosis; 
anti-contractile capacity 
 
1. Introduction  
Fibrotic diseases such as pulmonary fibrosis, cirrhosis, systemic sclerosis, interstitial nephritis and 
cardiovascular fibrosis are a threat to public health [1]. Constant high exposure to respirable particles 
is known to directly cause chronic inflammation-associated pulmonary diseases, including lung 
fibrosis and lung cancer [2]. These observations have resulted in increased research into mechanisms 
associated with fibrosis, the excessive fibrous connective tissue that underlies many chronic 
inflammatory pulmonary pathologies [1]. Indeed, studies have suggested that about 45% of deaths in 
developed countries are associated with fibrotic diseases of various organs [1].  
Fibroblasts, one of the most abundant cells in the interstitial tissues, are known to play an important 
role in inflammation and fibrogenesis [1,3]. Interactions between fibroblasts and the local 
microenvironment can induce the formation of self-perpetuating circuits of inflammation [4]. These 
circuits can maintain the prolonged and elevated excellular matrix (ECM) secreting phenotype of 
fibroblasts, which is the defining characteristic of fibrotic diseases. Therefore, the search for leading 
compounds, particularly those obtained from a natural resource, that target fibroblasts represents an 
emerging pharmacological and therapeutic focus against fibrotic diseases. 
Mangrove and its derived actinobacteria strains, are well-known for producing novel secondary 
metabolites and possessing highly effective bioactive compounds, possibly due to biochemical 
adaptation to the special intertidal ecosystem [5–9]. For example, in studies of anti-inflammatory 
compounds, 7-deacetylgedunin from Xylocarpus moluccensis was found to inhibit nitric oxide 
production in activated macrophages [10]. In another study, diterpenoids from Excoecaria agallocha L. 
were observed to suppress expression of NF-κB and AP-1 (activating protein-1) targeted genes 
including TNF-α and IL-6 in mouse macrophages [11]. Surfactin isomers from the mangrove 
bacterium  Bacillus sp. were also tested on the previous two models [12]. Finally, a mixture of 
Acanthus ilicifolius leaf extract was also shown to exhibit inhibitory activity in rat paw edema [3]. The 
immense and untapped microbial biodiversity in the mangrove is a promising resource for   
marine-derived leading therapeutic compounds.  
Streptomyces xiamenensis strain  318 was identified as a novel species of actinobacteria from 
mangrove sediments  [13]. During our preliminary screening for anti-fibrotic compounds, a crude 
extract of S. xiamenensis was tested in an adhesion-bioassay of fibroblasts on monocytes, and showed Mar. Drugs 2012, 10 
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inhibitory activity. Further studies were then carried out to identify and characterize the active 
ingredient in this extract. In our work, an alkaloid, N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-
methyl-3′S-pentenyl)-2H-1-benzopyran-6-yl]carbonyl]-threonine (1), was isolated from crude extracts 
of S. xiamenensis (Figure 1.) and demonstrated to have considerable bioactivity. Compound 1 was 
previously isolated from Streptomyces sp. Mer-88, and shown to inhibit binding between LFA-1 and 
ICAM-1, and suggested to have important anti-inflammatory properties [14]. The absolute 
configurations of compound 1 , including four stereogenic centers, were determined by extensive 
spectroscopic data analyses, Mosher’s method, Marfey’s reagent and quantum mechanical (QM) 
calculations. Compound 1 was found to exhibit inhibitory effects on cell proliferation of human lung 
fibroblasts (WI26), the contractile capacity of WI26 cells in a three-dimensional free-floating collagen 
gels, and the adhesion of human acute monocytic leukemia cells (THP-1) on a WI26 monolayer. As 
these properties are thought to contribute to the development of fibrosis, these data suggest that the 
compound described herein might indeed prove to be of considerable therapeutic benefit against 
fibrotic pathologies. 
2. Results and Discussion 
2.1. Isolation and Structural Elucidation of Compound 1  
Crude extracts from S. xiamenensis were assayed for their inhibitory effect on the adhesion of THP-1 
cells on a monolayer of WI26 cells. After incubating the crude extract (50 μg/mL) for 3 h, the adhesion 
of the THP-1 cells was about 15% lower than that with the solvent control (0.01% DMSO). Thus, the 
extract showed inhibitory adhesion activity and S. xiamenensis was considered as a promising 
bioactive resource for further chemical analyses. Guided by this bioactivity, a series of alkaloids were 
detected, using TLC and UPLC-MS, as the main secondary metabolites from the mixture extracted in a 
solution of ethyl acetate: methanol: formic acid = 80:15:5. The presence of pseudo-molecular ions  
[M + H]
+ at m/z  392.2069 and [M − H]
− at m/z  390.1886 in positive and negative ion modes, 
respectively, in the mass spectra, led to the purification of the main component, compound 1.  
Figure 1. Structure of compound 1 isolated from Streptomyces xiamenensis. 
 
1 
The molecular formula of 1 is C21H29NO6 based on HRESIMS, which is in accordance with the 
previous literature [14]. In the 
1H NMR spectrum of 1, three aromatic protons with signals at δH 7.63 
(1H, d, J = 8.4 Hz), 6.81 (1H, d, J = 8.4 Hz), 7.76 (1H, s), and 7.78, (1H, d, J = 7.8 Hz), as well as a 
high-field double-bond proton at δH 5.12 (1H, dd, J = 7.1, 1.3 Hz) were detected (Table 1). Carbon 
signals in the 
13C NMR spectrum consisted of six aromatic carbons, plus two olefinic carbons, two 
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carbonyl groups, two hydroxylated carbon signals at δC 79.8, 66.3, and a methylene at δC 31.2   
(Table 1), which is in accordance with the structure of a benzopyran moeity, attached to two side 
chains, threonine and isoprenylmethyl group. The HMBC correlations (Table 1) further confirmed the 
planar structure of 1, named N-[[3,4-dihydro-3-hydroxy-2-methyl-2-(4′-methyl-3′-pentenyl)-2H-1-
benzopyran-6-yl]carbonyl]-threonine [14].  
Table 1. 
1H and 
13C NMR spectroscopic data of compound 1 and Δδ
RS values of key  
H-atoms in (R)- and (S)-MPA diesters 
a. 
Position 
1    R/S-MPA-1 
δH (J in Hz)  δC, type  HMBC  δ
R  δ
S  Δδ
RS 
1  --  --        
2  --  79.8, C        
3  3.77, t 
b  66.3, CH  4a, 2, 9, 15      
4 
2.71, dd (17.3, 7.4) 
2.98, dd (17.3, 5.2) 
31.2, CH2  8a, 5, 4a, 2, 3 
2.54 
3.09 
2.82 
3.23 
−0.28 
−0.14 
4a  --  120.6, C       
5  7.67, s  129.8, CH  7, 8a, 4, 1′      
6  --  126.0, C       
7  7.63, d (8.4)  127.2, CH  5, 8a, 1′      
8  6.81, d (8.4)  116.7, CH  4a, 8a, 6      
8a  --  156.1, C       
9  1.60, m  38.0, CH2  11, 12, 2,3 
1.55 
1.47 
1.29 
1.21 
+0.26 
+0.26 
10  2.10, m  21.6, CH2  11, 12  2.05  1.95  +0.10 
11  5.12, dd (7.1, 1.3)  124.8, CH  13, 10, 14, 9  5.01  4.89  +0.12 
12  --  131.3, C       
13  1.57, s  17.9, CH3  11  1.51  1.47  +0.04 
14  1.65, s  25.9, CH3  11  1.60  1.58  +0.02 
15  1.18, s  18.7, CH3  2, 3, 9  1.27  0.97  +0.30 
1′  --  166.6, C       
2′  7.78, d (7.8)  --  1′  8.29  8.40  −0.11 
3′  4.38, brd  58.9, CH  4′, 6′  4.81  4.84  −0.03 
4′  4.18, brs  67.1, CH       
5′  1.12, d (6.0)  20.9, CH3   1.27  1.10  +0.17 
6′  --  172.8, C       
            
a Measured in DMSO-d6, Chemical shifts (δ) in ppm; 
b Measured in [D4]-methanol,  δH 3.88,   
dd (7.4, 5.2). 
2.2. Absolute Configurations of Compound 1 
The absolute configurations of 1, with four stereogenic centers, were identified by Mosher’s 
method, Marfey’s reagent, NOESY experiment, and QM calculations. Compound 1 was treated with 
(R)- and (S)-α-methoxy-α-phenylacetic acid (MPA) to form (R)- and (S)-MPA diesters. Diagnostic 
Δδ
RS sigals of the (R)- and (S)-MPA diesters resulted in negative Δδ
RS values for 4-H2 (Table 1), which Mar. Drugs 2012, 10 
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were in contrast to the positive Δδ
RS values for 9-H2, 10-H2, 11-H, 13-H3, 14-H3 and 15-H3, which are 
all related to the dihydropyran moiety. These data are in accordance with a 3S configuration of 1. The 
absolute configuration of the neighboring position 2 was then determined by elucidating the relative 
configuration related to 3S. The NOE correlation between 2-H3 and 4-Ha demonstrated that 2-H3 was 
in an axial orientation. The other NOE interaction between 2-H3 and 3-H demonstrated that 3-H was 
equatorially oriented and 3-OH was in a trans  configuration to 2-H3 (Figure 2). The relative 
configuration of 2-H3, 3-H and 4-Ha/e were further confirmed from the values of the coupling 
constants, which were 4-Ha (2.71, dd, 17.3, 7.4) and 4-He (2.98, dd, 17.3, 5.2).  
Figure 2. Key NOE correlations of the dihydropyran moiety in compound 1. 
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QM calculations on a model molecule of 2,2-dimethyl-3,4-dihydro-2H-pyran-3-ol indicate that, 
compared to that at the equatorial position, the 3-OH group prefers the axial position by about   
1.2 kcal/mol both in the gas phase and in DMSO solvent due to the gauche effect [15]. In the gauche 
conformation, the H-H distances of 2-H3 are as close as 2.55 Å to 3-H, and 2.30 Å to 4-Ha. The results 
are consistent with the key NOE correlations (Figure 2). Based on the absolute configuration of C-3 
and the relative configuration of C-2, we therefore identified the absolute configuration of position 2 to 
be 2S. 
As far as the other two stereocenters in the threonine moiety, diagnostic Δδ
RS sigals of the (R)- and 
(S)-MPA diesters resulted in negative Δδ
RS values for 3′-H and 2′-NH (Table 1), which were in 
contrast to the positive Δδ
RS values for 5′-H. The configuration of the position 4′ was thus assigned to 
be R. In order to determine the configuration at the position 3′, 1 was hydrolyzed in hydrochloric acid 
and then derivatized with 1-fluoro-2,4-dinitrophenyl-5-L-alanine (FDAA, Marfey’s reagent) [16]. 
Based on the results of hydrolyzation of 1 and derivatization with Marfey’s reagent afterwards, the 
threonine moiety was assigned as the naturally occurring structure of L-threonine [(2S,3R)-2-amino-3-
hydroxy butanoic acid]. The absolute configuration of 1 was therefore determined to be   
N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-methyl-3′S-pentenyl)-2H-1-benzopyran-6-yl]carbonyl]-
threonine (1). 
2.3. Inhibition of Proliferation on Human Diploid Lung Fibroblast (WI26) Cells by Compound 1. 
Fibrosis is characterized by the overgrowth, hardening, and/or scarring of various tissues and is 
attributed to an excess deposition of ECM components including collagen [1]. To combat this, an 
ability to slow down rapid fibrotic response during typical wound repair and tissue regeneration 
processes would seem to be a reasonable intervention, with the goal to avoid an accumulation of  Mar. Drugs 2012, 10 
 
644
non-functional fibrotic tissue and thereby enable transformation to more regenerative conditions [3].  
We thus investigated the anti-proliferative activity of 1 to this end. Lung fibroblast WI26 cells were 
exposed to 1, at a concentration of 30 µg/mL, for 0, 2, 3, 4 and 6 days, and the optical density (OD)  
λ = 450 nm was monitored as a function of time. As illustrated in Figure 3, compound 1 significantly 
inhibited the proliferation of WI26 cells. The extent of this inhibition increased with time (Figure 3), 
from a decrease of 7% at day 2 to 27% at day 6, compared with solvent control. Compound 1 therefore 
indeed exhibits anti-proliferative effects on lung fibroblast cells. 
Figure 3. Inhibitory effect of compound 1 on WI26 cells proliferation. The WI26 cells 
were exposed to 30 µg/mL of 1 at day 0, 2, 3, 4 and 6. Surviving fraction was determined 
by Cell Counting Kit-8 assay. As illustrated, proliferation of WI26 cells was significantly 
inhibited by 1 in a time-dependent manner. Data are given as the mean of triplicate   
values ± SD of three independent experiments. Significant differences from the value of 
0.1% DMSO solvent control were marked ** p < 0.01, *** p < 0.001. 
 
2.4. Effect of Compound 1 on the Adhesion of THP-1 Cells to a Monolayer of WI26 Cells 
Monocytes and macrophages have been shown to play pivotal roles in inflammation and fibrosis by 
modulating the secretion of cytokines as well as recruiting and activating fibroblasts and other 
inflammatory cells [17]. Direct contact between monocytes/macrophages and fibroblasts is important 
for the initiation, perpetuation, and resolution of fibrosis [18]. We therefore also evaluated the   
anti-adhesion bioactivity of 1. WI26 cells were first grown as a cell monolayer on a rigid tissue culture 
support, and then monocytic THP-1 cells were added to this monolayer. The number of adhered cells 
was then measured by optical microscopy after a 3 h incubation with either 1 (30 μg/mL) or 0.1% 
DMSO. As shown in Figure 4, there were obvious differences between the experiments with 1 present 
compared with those of the solvent control (Figure 4). Namely, the adhesion of THP-1 was about 41% 
lower in the presence of 1 than that in the solvent control. Thus, compound 1 exhibits significant  
anti-adhesion bioactivity for monocytes on fibroblasts. 
 Mar. Drugs 2012, 10 
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Figure 4. Blocking adhesion of THP-1 cells onto a monolayer of WI26 cells by compound 1. 
Representative pictures of the adhering cells taken with 400 fold magnification. Equal 
numbers of THP-1 cells with 1 (30 μg/mL) or 0.1% DMSO were added to a monolayer of 
WI26 cells in triplicate wells of 24-well plates, respectively. Adhering THP-1 cells after  
3-h-incubation were counted in four random visual fields of each well. (A) The attachment 
of THP-1 cells (marked by arrows) onto confluent WI26 cells, treated with 0.1% DMSO; 
(B) The attachment of THP-1 cells onto confluent WI26 cells, treated with 1 (30 μg/mL). It 
is clear from these images that adhesion of THP-1 cells was significantly blocked by 1.  
Bar = 25 μm. Each point represents the mean ± SD of three independent experiments. 
Significant difference from the value of 0.1% DMSO solvent control was marked,   
* p < 0.05. 
 
2.5. Effects of Compound 1 on Contraction of WI26 Cells in 3D Collagen Lattices 
It is widely known that mechanical force plays a contributing role in inflammation and fibrotic 
processes [19,20]. Not surprisingly, the contractible force generated by fibroblasts is a focus of much 
research [21]. Activated fibroblasts express many stress fibers which can facilitate wound repair [3] 
and fibrogenesis [22], while at the same time mechanical stress can promote inflammation and fibrosis 
by activating fibroblasts and inflammation cells [19,23]. In order to evaluate the anti-contractility 
activity of 1, three-dimensional collagen lattices were used as a richer, perhaps more physiologically 
relevant physical environment, that can enable direct investigation of the interactive process of 
fibroblast-collagen matrix remodeling [24]. WI26 cells were seeded in free-floating collagen gel 
lattices, followed by the application of 1 or solvent control. As shown in Figure 5A, the presence of 
compound 1 significantly delayed contraction of the collagen gel. After 1, 2, 3 and 6 h, the contraction 
was markedly decreased compared to solvent control by 21%, 22%, 18% and 8%, respectively (Figure 5B).  Mar. Drugs 2012, 10 
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Figure 5. Compound 1 inhibited contractile ability of WI26 cells in 3D collagen lattices. 
Equal numbers of WI26 cells were seeded in triplicate gels of collagen I with compound 1 
(30  μg/mL) or 0.1% DMSO. The contraction of collagen gel was monitored by 
photographing the gels at appointed time intervals. (A) As illustrated, contraction of 
collagen gel was attenuated by compound 1 compared to 0.1% DMSO at different time 
points. The edge of gel was marked with dots. (B) The area of the gel was measured and 
plotted as a percentage of the original area at the onset of the experiments. Each point 
represents the mean ± SD of three independent experiments. Significant differences from 
the value of 0.1% DMSO solvent control were marked, * p < 0.05, ** p < 0.01. 
 
 
2.6. Discussion 
Today, fibrotic diseases are becoming more threathening than ever, due to enviromental pollution. 
It has been reported that high levels of air pollutant paticles can induce chronic fibrotic responses in 
airways [25]. Identification of bioactive molecules that affect fibrosis is thus becoming a promising 
theraputic area and also an urgent task. For example, the synthetic drug TAS-301, a constrictive 
remodeling regulator, was shown to have high inhibitory potency on coronary artery stenosis, mainly 
due to inhibition of adventitial fibroblast proliferation and the contractile ability of myofibroblasts [26]. 
During excessive fibrogenesis, it is well known that self-perpetuating circuits of inflammation and 
ECM accumulation, and constriction by inflammation and mechanical force, directly influence the 
development of fibrotic diseases [4]. Hence, the development of leading compounds aimed at these 
circuits may target the effects on these diseases, while avoiding severely disturbing physiological 
processes induced by steroidal anti-inflammatory drugs. 
Fibroblasts play pivotal roles in establishing and maintaining these circuits and are in fact the main 
ECM generating cells in fibrotic diseases [27]. During these diseases, resident fibroblasts proliferate 
and are activated as a result of stimulation by injury or inflammation. The activated fibroblasts contribute 
to ECM production and inflammatory modulation [28]. Radiotherapy and chemotherapeutics are Mar. Drugs 2012, 10 
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useful for treating hypertrophic scar and keloid development by inducing apoptosis of fibroblasts [29]. 
Compound 1 showed inhibitory effects on fibroblast proliferation, and thus may contribute to the 
alleviation of excessive fibrotic accumulation. 
Activated fibroblasts may also convert into myofibroblasts, which express many more stress fibers 
and generate much more mechanical tension [1]. The mechanical force generated by endogenous 
fibroblasts has been found to play important roles in the activation and secretion of inflammatory  
cells [19,23,30]. It has been demonstrated that reduction of mechanical stress can alleviate 
inflammation and fibrosis in vivo [12]. Therefore, mechanical force and local inflammation together 
comprise one of the most important self-perpetuating inflammatory circuits that, underlies many 
fibrotic diseases. Compound 1 can reduce the contractile capability of fibroblasts, thus indicating a 
potential to inhibit this key aspect of fibrogenesis. 
The interaction of monocytes and fibroblasts is known to play an important role in   
inflammation [17,31]. Direct contact between monocytes and fibroblasts can faciliate the activation of 
both cells [32]. Compound 1 blocked the adhesion of fibroblasts and monocytes, which may 
ameliorate excessive inflammatory processes in fibrotic diseases. In previous investigation, 1 was 
reported as an antagonist of the LFA-1/ICAM-1 interaction [14]. Since LFA-1/ICAM-1 can mediate 
direct contact of inflammatory cells and fibroblasts [33], the LFA-1/ICAM-1 binding inhibitory effect 
may explain the results of the adhesion experiment. 
In conclusion, 1 has multiple biological effects on lung fibroblast properties, including proliferation, 
contractile capacity and interaction with monocytes, which are likely to be involved in the 
establishment of positive feedback circuits that lead to excessive fibrosis.  
Although pathological fibrosis of different organs is common in many diseases [1], there are 
presently very few therapeutic options [34]. Anti-inflammatory drugs such as corticosteroids can 
prevent pathological fibrosis [29,35], but long-term use and high dosage are unsuitable owing to their 
extensive adverse effects [36,37]. Superficial compression is useful for preventing the development of 
skin hypertrophic scars [29], but this procedure cannot be used in visceral organs. The “vicious cycle” 
of fibroproliferation is one of the most important characteristics of pathological fibrosis [19,23]. 
Hence, small molecules that target the positive feedback circuits may prove tremendously effective in 
exhibiting antifibrotic activities without severe side effects. The results presented herein illustrate that 
compound 1 may serve as a useful antifibrotic leading compound for treating pulmonary fibrosis and 
other pathological fibrotic diseases. 
3. Experimental Section  
3.1. General  
1H and 
13C NMR spectra were recorded with Bruker DRX-500 and Avance III-600 NMR 
spectrometers with the solvent as an internal standard (DMSO-d6 δ = 2.51 and 40.0 ppm, respectively). 
Chemical shifts (δ) expressed in parts per million (ppm) and coupling constants (J) are reported in 
Hertz (Hz). LC-HRMS was performed on a Waters ACQUITY UPLC system equipped with a binary 
solvent delivery manager and a sample manager, coupled with a Waters Micromass Q-TOF Premier 
Mass Spectrometer equipped with an electrospray interface (Waters Corporation, Milford, MA). Mar. Drugs 2012, 10 
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Column chromatography was performed with silica gel (200–300 mesh, Qingdao Marine Chemical, 
Inc., Qingdao, China), silica gel H (10–40 μm, Qingdao), Sephadex LH-20 (40–70 μm, Amersham 
Pharmacia Biotech AB, Uppsala, Sweden) and Lichroprep reversed-phase RP-18 silica gel (40–63 μm, 
Merck, Darmstadt, Germany). The chemical reagents used for chromatography were purchased from 
Shanghai Chemical Works Co. Ltd. (Shanghai, China). Optical rotations were recorded on a JASCO  
P-2000 polarimeter. CD spectra were taken on a J-815 spectropolarimeter (JASCO, Gross-Umstadt, 
Germany) at room temperature. An Agilent 1200 series system was used for the analytical scale 
method. Analytical HPLC was carried out on an Welch XB-C18 column (4.6 × 150 mm, 5 μm, Welch 
Materials, Inc., USA), flow 1 mL/min. Organic solvents for HPLC were analytical grade and were 
purchased from Shanghai ANPEL Scientific Instrument Co. Ltd. (Shanghai, China). 
3.2. Strain Cultivation 
Streptomyces xiamenensis strain 318 was isolated from a mangrove sediment sample collected in 
the national mangrove reserve in Fujian province of China [13]. Spores of strain 318 were inoculated 
on GYM (Glucose 4 g, Yeast extract 4 g, Malt extract 10 g, CaCO3 2 g, Agar 12 g, Distilled water 1 L, 
adjusted to pH 7.2 with KOH before adding agar.) plates were then incubated at 28 ± 1 °C for 12 days 
before harvesting.  
3.3. Extraction and Isolation 
The 30 L plate culture of S. xiamenisis was extracted with a solvent mixture of ethyl 
acetate/methanol/acetic acid (80:15:5, v:v:v) at room temperature overnight. The supernatant was 
filtered and the residue was then extracted twice as described above. The total supernatants were 
combined and concentrated under vacuum at 37 °C in order to remove the organic part to afford a 
crude extract (12 g). Half of the crude extract was subjected to column chromatography on silica gel, 
eluted by CH2Cl2:MeOH (gradient from methanol, 100:1, 50:1, 20:1, 10:1, 5:1 to MeOH). The fraction 
[eluted with CH2Cl2:MeOH (10:1, v:v)] was collected and purified by repeated column chromatography 
on Sephadex LH-20, which was washed by MeOH. The fractions were collected and guided by HPLC 
fingerprints to find peaks containing the target UV profile (λmax 206, 260 nm). Finally, the combination 
was separated by ODS column (eluted with MeOH:H2O = 75:25) to obtain compound 1 (15 mg).  
N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-methyl-3′S-pentenyl)-2H-1-benzopyran-6-yl] 
carbonyl]-threonine (1): Yellow amorphous powder (MeOH); [α]
22
D +39.5° (c 0.044, MeOH); UV  
λmax (MeOH) 206, 260 nm; CD (MeOH) Δε201 +0.15, Δε202 +0.55, Δε205 +0.3, Δε207.5 +0.5,  
Δε229 −0.05, Δε259 +0.28; 
1H and 
13C NMR data, see Table 1; HRESIMS m/z 392.2069 [M + H]
+, 
(calcd for C21H30NO6, m/z 392.2073), 390.1886 [M − H]
−, (calcd for C21H29NO6, m/z 390.1917). 
3.4. (R)- and (S)-MPA Esterification 
(R)-MPA (4.0 mg), dicyclohexylcarbodiimide (DCC), and catalytic N,N-dimethylpyridin-4-amine 
(DMAP) were added to a CHCl3 solution of compound 1. The mixture was stirred for 2 h to yield  
(R)-MPA ester of 1. The (S)-MPA ester (1.1 mg) was obtained by the same protocol as for (R)-MPA 
ester (1.2 mg).  Mar. Drugs 2012, 10 
 
649
3.5. Hydrolysis of Compound 1, Derivatization with Marfey’s Reagent  
Compound 1 (1.0 mg) was hydrolyzed in 1:1 hydrochloric acid-acetic acid at 100 °C for 18 h,  
500 μL H2O was added and the mixture was lyophilized overnight [16]. Then 200 μL of 1 M NaHCO3 
and 400 μL of 38.7 μM FDAA (Sigma-Aldrich, St. Louise, MO, USA) in acetone were added to the 
mixture for derivatization. The solution was vortexed and incubated at 40 °C for 60 min. Reactions 
were quenched by addition of 100 μL of 2M HCl. Samples were diluted 1:2 with HPLC initial mobile 
phase. The derivatization of L-Threonine (Sangon, Shanghai, China) and D-Threonine (Sangon, 
Shanghai, China) were prepared in the same way. Then the samples were analyzed by HPLC with UV 
detection at 340 nm and further confirmed by UPLC-MS. 
3.6. Cell Culture 
The WI26-SV40 transformed human lung fibroblast [American Type Culture Collection (ATCC) 
CCL 95.1] cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Grand 
Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, GIBCO-BRL, Gaithersburg, MD, 
USA), 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (Solarbio, Beijing, China). 
THP-1 (human acute monocytic leukemia cell line) cells were maintained in RPMI 1640 meted with 
10% fetal bovine serum (FBS, GIBCO-BRL, Gaithersburg, MD, USA), 2 mM L-glutamine, 100 U/mL 
penicillin and 100 μg/mL streptomycin (Solarbio, Beijing, China). THP-1 (human acute monocytic 
leukemia cell line) cells were maintained in RPMI 1640 medium (Gibco, Grand Island, NY, USA), 
supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 
0.5 mM/L β-mercaptoethanol (Gibco, Grand Island, NY, USA). Both kinds of cells were incubated at 
37 °C humidified atmosphere of 5% CO2 in air. 
3.7. Cell Proliferation Assay 
The effect of compound 1 on cell proliferation was determined using a standard Cell Counting  
Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) assay according to the manufacturer’s instruction. WI26 
cells at 70%–80% confluent were trysinized by 0.25% trypsin-0.02% EDTA solution, centrifuged and  
re-suspended in DMEM supplemented with 10% FBS and antibiotics and seeded in 96-well plates 
(100 μL/well) at an initial density of 2.5 × 10
4 cells/mL. The medium was replaced 24 h later by fresh 
DMEM with 10% FBS and antibiotics containing 30 μg/mL compound 1 or 0.1% DMSO (AppliChem, 
Darmstadt, Germany), then the medium was refreshed and the cells viability was measured by using 
CCK-8 solution at day 0, 2, 3, 4 and 6, respectively. Proliferation measurement was applied by adding 
10 μL CCK-8 solutions to each well and incubating at 37 °C for 1 h. The OD values of each well were 
measured at the primary wavelength λ = 450 nm by using a Microplate Spectrophotometer 
(PowerWaveXS, BioTek, Seattle, WA, USA). Data are shown as means ± standard deviation (SD) of 
three independent experiments, each performed in triplicate. 
3.8. Cell Adhesion Assay 
Two days before adhesion assay, WI26 cells were seeded in 24-well plates (500 μL/well) at a 
density of 3 × 10
5 cells/mL and allowed to grow 24 h to confluence. The medium of THP-1 and WI26 Mar. Drugs 2012, 10 
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cells was replaced by DMEM supplemented with 0.5% FBS and antibiotics 24 h before the adhesion 
experiment. The culture of THP-1 cells was centrifuged at 1000 rpm for 5 min. The supernatant was 
discarded. The THP-1 cells were re-suspended in DMEM with 10% FBS and antibiotics, then diluted 
to 5 × 10
5 cells/mL. The medium of WI26 cells in 24-well plates was discarded to get a monolayer of 
WI26 cells in each well, then 500 μL THP-1 suspension was added into each well as previously 
published [38,39]. For the biotest groups, 30 μg/mL compound 1 or 50 μg/mL crude extract of   
S. xiamenensis culture was added in each well, respectively. For the control groups, 0.1% DMSO was 
used as solvent control for 1 and 0.01% DMSO as solvent control of crude extract, respectively, 
according to the different final DMSO concentration of 1 and crude extract. Two kinds of cells were 
co-cultured for 3 h, then the medium and the non-adherent THP-1 cells were removed by washing with 
PBS three times. Adherent THP-1 cells were quantified microscopically at 400-fold magnification in 4 
random visual fields of each well and photographed with a digital camera (LY-WN-HPCCD, China) 
mounted on a microscope (Olympus, CKX31, Japan). Data are shown as means ± standard deviation 
(SD) of three independent experiments, each performed in triplicate. 
3.9. Fibroblast Contraction Assay 
WI26 cells at 70%–80% confluent were trysinized by 0.25% trypsin-0.02% EDTA solution and 
seeded at a density of 4 × 10
5 cells/mL into 32 mm bacteriological plates (2 mL/dish) in DMEM 
supplemented with 10% FBS, antibiotics, sodium ascorbate (50 μg/mL), and containing 0.3 mg/mL of 
acid-extracted collagen I from newborn calf skin (IBFB, Leipzig, Germany) as previously   
described [40]. For the biotest groups, 30 μg/mL pure extract of compound 1 was added in each well; 
for the control groups, 0.1% DMSO was used as solvent control. The cultures were placed at 37 °C for 
60 min to allow collagen polymerization, and then the gels from plates were released by tilting the 
plates slightly. Gradual lattice contraction was monitored by measuring the gel area of triplicate setups 
at successive time points up to 6 h. Data are shown as means ± standard deviation (SD) of three 
independent experiments, each performed in triplicate. 
3.10. Statistical Analysis 
Statistic differences were calculated using student’s paired t-test at a significance level of p < 0.05 
to 0.001.  
3.11. Computational Methods 
The QM calculations were carried out with the M06-2X hybrid meta DFT functional with the  
6 − 31 + G(d,p) basis set using Gaussian 09. Conformations were fully optimized and characterized by 
harmonic vibrational frequency analysis. The solvation energies in DMSO were calculated with 
Truhlar’s SMD solvation model [41–43].  
4. Conclusions  
The investigation of anti-fibrosis small molecules derived from S. xiamenensis may represent an 
emerging pharmacological and therapeutic area for fibrotic diseases. The structure and   Mar. Drugs 2012, 10 
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absolute configurations of N-[[3,4-dihydro-3S-hydroxy-2S-methyl-2-(4′R-methyl-3′S-pentenyl)-2H-1-
benzopyran-6-yl]carbonyl]-threonine (1) was fully elucidated by extensive spectroscopic data analyses, 
Mosher’s method, Marfey’s reagent and QM calculations. The multiple biological effects of 1 on lung 
fibroblast behavior were investigated, including proliferation, anti-contractile capacity and anti-adhesion 
with monocytes. These three bioactive aspects are involved in the construction of positive feedback 
circuits of excessive fibrosis. Developing leading compounds from marine natural products, aiming at 
these circuits may have targeted effects on fibrotic diseases. 
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